The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert announcing the recall of two substandard antibiotic suspensions manufactured by Sam-Ace Ltd in Nigeria.
According to Public Alert No. 34/2025, the affected products are Astamocil (Amoxicillin Suspension 125mg/5ml), Batch No. 826024, and Astamentin (Amoxicillin/Clavulanic Acid Suspension 228.5mg), Batches 0503024 and 0501724.
The agency stated that the products were discovered during a recent Risk-Based Post-Marketing Surveillance conducted at the Coordinated Wholesale Centre (CWC) in Kano. Laboratory analysis revealed that both suspensions failed quality tests due to low Active Pharmaceutical Ingredient (API) content, making them substandard and ineffective for treating infections.
As a result, NAFDAC has directed Sam-Ace Ltd to immediately recall all affected batches from circulation.
Amoxicillin, a penicillin-class antibacterial, is commonly prescribed to treat infections of the ear, nose, throat, genitourinary tract, skin, and lower respiratory tract. The combination of Amoxicillin and Clavulanic Acid is used to treat a broader range of bacterial infections, including sinusitis, pneumonia, bronchitis, and urinary tract infections.
NAFDAC warned that the use of substandard antibiotics could lead to treatment failure and antimicrobial resistance, posing serious risks to public health.
The agency urged healthcare professionals, distributors, and the public to report any suspected sale or distribution of substandard or falsified medicines to the nearest NAFDAC office, via the toll-free number 0800-162-3322, or by email at sf.alert@nafdac.gov.ng.
For further details, visit the official NAFDAC alert page: https://bit.ly/47u4iaA.